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Abstract 
The present study evaluates the potential of improved third-generation lentivirus vector with 
respect to their use as an in vivo-administered T-cell vaccine against tuberculosis.  Intratracheal 
administration of the lentivirus vector encoding MPT51 of Mycobacterium tuberculosis could 
induce MPT51-specific CD8+ T cells in the mediastinal lymph nodes 2 weeks after the 
administration.  The vaccination could generate MPT51-specific memory CD8+ T cells in the 
lung, but not in the lymph nodes.  Further, a single intratracheal immunization of MPT51 
lentiviral vaccine decreased significantly the number of virulent M. tuberculosis in the lung after 
intratracheal challenge of the bacillus.  These findings suggest that intratracheal immunization of 
the third-generation lentiviral vaccines is a promising vaccination strategy against pulmonary 
tuberculosis. 
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1. Introduction 
Tuberculosis (TB) has been a major cause of death by infectious diseases worldwide.  There 
were an estimated 8.8 million new TB cases in 2005, and 1.6 million people died of TB [1].  An 
attenuated strain of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) is only currently 
available anti-TB vaccine which is effective against the severe child forms of TB, yet its efficacy 
against pulmonary TB in adult is controversial [2].  It is evident that there is an urgent need for a 
novel and more reliable anti-TB vaccine [3].   
Although the mechanisms of protection against TB have not been completely determined, 
cell-mediated immunity plays an important role in the control of M. tuberculosis infection.  
There is mounting evidence that type 1 helper T cells are involved in the development of 
resistance to the disease, primarily through the production of macrophage-activating cytokines, 
such as interferon-γ (IFN-γ) [4].  In addition, CD8+ cytotoxic T-lymphocytes (CTL) contribute to 
disease resistance since susceptibility to M. tuberculosis is greater in mice deficient in CD8+ T 
cells [5].   
Dendritic cells (DC) are the most potent antigen-presenting cells.  DC capture bacteria and 
other pathogens.  Then, they migrate to regional lymphoid organs, where they present antigens 
(Ag) to naïve T cells [6].  DC are also known to confer T cells the ability to home to 
non-lymphoid sites.  Activated effector/memory T cells migrate preferentially to tissues that are 
connected to the secondary lymphoid organs where Ag first encountered [7].  In this context, 
intratracheal vaccination is an attractive option to induce protective immunity against TB at the 
lung.  In fact, M. bovis BCG administered via the respiratory route has been shown to be more 
effective than when it was given subcutaneously [8-11].  However, intratracheal administration 
of M. bovis BCG may cause severe inflammation in the trachea.  For the intratracheal 
vaccination, such risk of adverse reactions should be avoided.  The development of recombinant 
viral vector systems for gene therapy has prompted examination of their efficacy in gene delivery 
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to DC and in direct immunization.  Adenovirus vectors were shown to deliver Ag genes to DC.  
However, pre-existing immunity to viral proteins expressed by the vector prevented effective 
immunization [12].  Retroviral vectors based on murine leukemia virus have been employed to 
express Ag in DC [13].  However, the retroviral vectors only infect dividing cells.   
Lentiviral vectors have been shown to efficiently transduce a variety of nondividing cells, 
including DC [14].  Successful transduction of DC with lentiviral vectors has been reported 
[15-17].  In addition, lentiviral vectors pseudotyped with minimal filovirus envelopes have been 
reported to increase gene transfer in murine lung [18].  Third-generation self-inactivating (SIN) 
lentiviral vector was chosen in this study because of its advanced safety profile, allowing its 
administration in vivo, and because of the presumed absence of pre-existing anti-vector immunity.  
Our aim was to develop third-generation lentivirus vectors that express an M. tuberculosis Ag 
and efficiently induce cell-mediated immunity against pulmonary TB by the intratracheal 
instillation.  As a target Ag, we employed MPT51, the protective character of which we have 
shown in our previous report [19].   
 
2. Materials and methods 
2.1. Mice 
BALB/c mice (8 to14 weeks of age; Japan SLC; Hamamatsu, Japan) were maintained in the 
Animal Facility of Hamamatsu University School of Medicine.  All animal experiments were 
performed according to the Guidelines for Animal Experimentation, Hamamatsu University 
School of Medicine. 
2.2. Lentivirus vector production 
The improved third generation lentivirus system had been developed [14, 20, 21].  The 
system comprised of following plasmids.  pCAG-HIVgp is a packaging plasmid in which all 
accessory genes (vif, vpr, vpu, and nef) and regulatory genes (tat and rev) are deleted.  
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pCMV-VSV-G-RSV-Rev is an expression plasmid for vesicular stomatitis virus G glycoprotein 
and Rev protein.  The SIN plasmid, pCSII-CMV-MCS-IRES-EGFP contains a multiple cloning 
site and the gene encoding enhanced green fluorescent protein (EGFP).  MPT51 DNA fragment 
was inserted into the vector, resulted in pCSII-CMV-MPT51-EGFP.  The MPT51 recombinant 
lentivirus vector was generated by transient transfection of 293T cells with pCAG-HIVgp (10 μg), 
pCMV-VSV-G-RSV-Rev (10 μg), and pCSII-CMV-MPT51-EGFP (17 μg) plasmids using 10-cm 
dishes with DoFect-GT1 (Dojindo, Kumamoto, Japan) transfection reagent.  293T cells were 
cultured in Dulbecco’s modified Eagle medium (DMEM; Sigma-Aldrich, St. Louis, MO, USA) 
containing 10% heat-inactivated fetal calf serum (FCS; Invitrogen, Carlsbad, NM, USA).  
Culture supernatants were collected every 24 h for 3 days, filtered through a 0.45-mm pore size 
filter, and concentrated by two-times ultracentrifugation at 50000× g at 20°C for 120 min.  The 
viral supernatants were concentrated 1000 times with the ultracentrifugation, finally resuspended 
in sterile phosphate-buffered saline (PBS), and stored at -80°C until use.  The virus titers were 
determined on 293T cells by measurement of EGFP expression using flow cytometry.  Titers of 1 
to 2 × 108 infectious units (IU) ml-1 were usually obtained through the experiments. 
2.3. Intratracheal administration 
Mice were anesthetized with an intraperitoneal administration of 0.075 mg ketamine/0.015 mg 
xylazine per gram weight of mouse.  Intratracheal administration of 5 × 106 IU of MPT51 
lentivirus in 50 μl of sterile PBS was performed by infusion through the vocal cords using a fiber 
optic light source (LG-PS2, Olympus Optical, Tokyo, Japan) for illuminating the entrance into the 
trachea [22, 23]. 
2.4. Bronchoalveolar lavage (BAL) 
 Mice were killed and a midline incision was made to expose the trachea.  An 18-G catheter 
was inserted into the trachea, and the lungs were lavaged with 5 ml of ice-cold sterile PBS. 
Lavage cells were collected by centrifugation at 300× g for 10 min at 4°C and washed with PBS. 
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2.5. Lung tissue lymphocyte isolation 
Lungs were removed from mice, transported in RPMI 1640 medium (5 ml per lung; 
Sigma-Aldrich), and cut into small pieces (1-2 mm2) with a forceps.  Tissue pieces were digested 
with 3500 dornase units ml-1 of DNase I (Calbiochem, Darmstadt, Germany) and 75 units ml-1 of 
collagenase type II (Invitrogen) at 37°C for 2 h.  The digest was filtrated through a 70-μm 
nucleopore filter and centrifuged (300× g, 10 min).  The cell pellets were resuspended in PBS 
containing 0.01 M EDTA and chilled on ice for 5 min, and then subjected to centrifugation in 
Ficoll-Paque Plus solution (Amersham Pharmacia Biotech, Uppsala, Sweden) at 400× g and 20°C 
for 30 min.  The pulmonary mononuclear cell interface was collected, washed twice, and 
resuspended in 5 ml of RPMI 1640 medium containing 10% FCS (RPMI/10FCS) [24].   
2.6. Analysis of CD8+ T cells using MPT51 p24-32 peptide/H2-Dd tetramer complex 
An MPT51 p24-32 peptide/H2-Dd tetramer complex was kindly supplied by the NIH Tetramer 
Facility.  Cells were treated ammonium chloride and potassium chloride (ACK) lysis buffer for 5 
min at room temperature to remove erythrocytes and washed twice with RPMI 1640 medium and 
resuspended in RPMI/10FCS.  The 1 × 106 cells were stained with phycoerythrin 
(PE)-conjugated MPT51 p24-32 peptide/H2-Dd tetramer complex, fluorescein isothiocyanate 
(FITC)-conjugated anti-CD8 (53-6.7; BD PharMingen, San Diego, CA, USA), and 
PE-Cy5-conjugated anti-CD4 (RM4-5; BD PharMingen) monoclonal antibodies (mAb) at 4°C for 
30 min.  After washing, the cells were resuspended in PBS containing 0.1% sodium azide and 
1% bovine serum albumin, and then analyzed on an EPICS digital flow cytometer (EPICS XL; 
Beckman Coulter, Miami, FL, USA). 
2.7. Quantification of IFN-γ with cytokine enzyme-linked immunosorbent assay (ELISA) 
Spleen cells were harvested from the immunized mice.  Recovered cells were plated in 
24-well plates at 2 × 106 cells per well in the presence or absence of 1 μM of MPT51 p24-32 
peptide for 5 days.  Concentration of IFN-γ in the culture supernatants was determined by a 
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sandwich ELISA as described in our previous report [25]. 
2.8. Protection assay against M. tuberculosis infection 
Immunized mice were subjected with intratracheal injection of 1 × 104 CFU of M. tuberculosis 
H37Rv 10 weeks after MPT51 lentivirus immunization.  Mice were sacrificed 5 weeks later and 
the bacterial numbers in the lung were counted in CFU on Middlebrook 7H10 medium (Becton 
Dickinson, Sparks, MD, USA).  M. tuberculosis H37Rv was kindly donated by Dr. Isamu 
Sugawara (Research Institute of Tuberculosis, Tokyo, Japan). 
2.9. Statistics  
Data from multiple experiments were expressed as the means ± SD.  Statistical analyses were 
performed by using StatView-J 5.0 statistics program (SAS Institute, Inc., Cary, NC, USA).  Data 
were analyzed with one factor-analysis of variance followed by the Fisher’s protected least 
significant difference (PLSD) test. 
 
3. Results 
3.1. EGFP expression of cells in bronchoalveolar lavage fluid (BALF) of mice 
intratracheally-immunized with MPT51 lentivirus 
The lentivirus vector used in this study was pseudotyped with vesicular stomatitis virus 
glycoprotein and thus was taken up through the normal endocytotic pathway.  Therefore, it is 
able to transduce a wide variety of cells.  We first examined EGFP expression of cells in BALF 
after intratracheal administration of MPT51 lentivirus vector vaccine.  As shown in Fig. 1, EGFP 
expression was observed 1 week after lentivirus administration and the peak of expression was 
reached around two weeks after the administration.  This observation indicates that the cells in 
BALF, most of which are macrophages, are transduced by the lentiviral vector and that protein 
expression of transduced vector requires at least 1 week after the administration.  We also 
examined EGFP expression in the mediastinal lymph nodes (MLN).  Preferential EGFP 
 Hashimoto et al., manuscript for Vaccine 
 8
expression in CD11c+ cells in the MLN was observed 2 weeks after the administration (data not 
shown).   
3.2. Induction of MPT51-specific CD8+ T cells in the MLN 
To address whether intratracheal administration of lentiviral vector vaccine results in the 
induction of MPT51-specific CD8+ T cells in tissues, CD8+ T cells were monitored in the lung, 
MLN, and the spleen by staining with an MPT51 p24-32 peptide/H2-Dd tetramer.  As shown in 
Fig. 2, kinetic analysis revealed that the Ag-specific CD8+ T cells appeared 2 weeks after the 
administration in the MLN and the peak of response was reached around 3 weeks after that.  In 
contrast, there appeared no detectable Ag-specific CD8+ T cells in the lung and the spleen until 6 
weeks after the administration.   
3.3. Detection of MPT51-specific memory CD8+ T cells in the lung 
We then examined the lung cells derived from mice intratracheally-immunized with MPT51 
lentivirus for detection of MPT51-specific memory CD8+ T cells.  We isolated mononuclear 
cells from lungs of the immunized mice 10 weeks after the administration and stimulated them by 
MPT51 p24-32 peptide for 5 days.  Then, expansion of MPT51-specific CD8+ T cells in the lung 
and the MLN was evaluated in flow cytometry with MPT51 p24-32/H2-Dd tetramer and anti-CD8 
mAb staining.  As shown in Fig. 3, expansion of MPT51-specific CD8+ T cells was observed in 
the lung of MPT51 lentivirus-immunized mice, but not in the MLN of the immunized mice and in 
naïve mice, indicating that MPT51 lentivirus intratracheal administration was able to induce 
MPT51-specific CD8+ memory cells in the lung.   
3.4. Induction of protective immunity against M. tuberculosis by intratracheal MPT51 lentivirus 
administration 
We finally evaluated the effects of intratracheal administration of MPT51 lentiviral vector on 
induction of protective immunity against M. tuberculosis infection.  We intratracheally 
administered 1 × 104 CFU of M. tuberculosis H37Rv to mice 10 weeks after MPT51 lentivirus 
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immunization.  Five weeks after M. tuberculosis challenge, lungs were prepared from the mice 
and the CFU of M. tuberculosis were evaluated.  The CFU in MPT51 lentivirus-immunized mice 
were significantly lower than those of naïve mice as shown in Fig. 4.   
 
4. Discussion 
The present study evaluated the potential of third-generation lentivirus vector with respect to 
the use as mucosal anti-TB T-cell vaccine.  From data described above, we were able to draw the 
following conclusions.  (1) The intratracheal administration of the lentivirus vector encoding 
MPT51 from M. tuberculosis is capable of inducing specific CD8+ T cells in the MLN.  (2) 
MPT51-specific memory CD8+ T cells appear in the lung, but not in the MLN.  (3) A single 
intratracheal immunization of MPT51 lentiviral vaccine decreased significantly the number of 
virulent M. tuberculosis in the lung after intratracheal challenge of the bacillus. 
The development of a variety of TB vaccine systems has been reported in order to obtain more 
effective TB vaccines over BCG vaccine, which is a gold standard of TB vaccine for the time 
being.  Virus-based vaccine strategy is one of them.  Vaccinia virus-mediated TB vaccines have 
been reported.  Zhu and colleagues [26] showed that immunization with 19kDa- and 38kDa- 
glycol-lipoproteins of M. tuberculosis reduced the bacterial numbers of virulent M. tuberculosis 
bacillus in the lungs of immunized mice.  Vaccinia virus-based vaccines have been successfully 
used as a boosting vaccine following BCG- or DNA-based priming vaccination [27].  Adenoviral 
TB vaccines have been also examined in Dr. Xing’s group [28, 29].  Wang and colleagues [28] 
reported that a single mucosal, but not parenteral, immunization with recombinant 
adenoviral-based TB vaccine encoding antigen 85A of M. tuberculosis provides potent protection 
from pulmonary tuberculosis.   
We here showed that a single intratracheal MPT51 lentivirus administration was effective for 
inducing antigen-specific CD8+ T-cell responses in the lung.  To our knowledge, it is the first 
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report of lentivirus-based vaccine trial for TB.  Esslinger and colleagues [30] showed that 
lentiviral vector injection into the footpad of mice transduced DC that appears in the draining 
lymph node and in the spleen.  They showed that in vivo administration of lentivector was 
superior to transfer of transduced DC or peptide/adjuvant vaccination in terms of both amplitude 
and longevity of the CTL response.  The results in this present study further showed the 
effectiveness of lentiviral vector system for mucosal T cell-based vaccination.   
Mucosal immunization studies have been reported against airway M. tuberculosis infection.  
Gallichan and Rosenthal [31] showed that long-term mucosal CTL memory was observed only 
with mucosal, but not systemic, immunization with an adenoviral herpes vaccine.  Among a 
variety of mucosal immunization routes, intranasal vaccination is one of the promising 
immunization routes for various TB vaccines [9-11, 28, 29].  Giri and colleagues [32] showed 
that intranasal vaccination with antigen 85A and antigen 85B of M. tuberculosis induced a 
significantly higher level of IFN-γ, interleukin (IL)-12, and IL-4 in cervical lymph nodes over 
subcutaneous vaccination.  Further, intranasal vaccination with these Ag imparted protection 
against M. tuberculosis comparable with that obtained from intranasal or subcutaneous M. bovis 
BCG immunization.  Another route for eliciting mucosal immunity in the lung is intratracheal 
administration of vaccines [33].  The method of intratracheal injection used in this study is a 
simple and rapid method without any invasive procedure [22, 23], compared with conventional 
intratracheal infection method with tracheal incision step (e.g., [34]).  The present study showed 
the feasibility of the intratracheal intubation method of mucosal immunization for airway 
infections.   
We showed here that MPT51-specific memory CD8+ T cells generated in the lung after a 
single intratracheal instillation.  Kamath and colleagues [35] showed that CFP10-specific and 
TB10.3/4-specific CD8+ T cells are greatly enriched in the lung compared with other sites of 
infection such as spleen or lymph nodes.  They showed that CD8+ T cells are cytolytic in vivo 
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and their cytolytic activity could be detected even as late as 260 days after infection.  Servina and 
Flynn [36] also observed that at 1 week post challenge with M .tuberculosis via aerosol, over 30% 
of CD8+ and CD4+ T cells in the lungs of immune mice expressed the activation marker CD69 
and could be restimulated to produce IFN-γ, showing a rapid response of CD8+ and CD4+ T cells 
in the lungs following challenge.  These rapidly expanded CD8+ T cells in the lung are derived 
from lung-resident memory CD8+ T cells because we showed that lung mononuclear cells 10 
weeks after MPT51 lentivirus administration responded to MPT51 p24-32 peptide in vitro and 
produced IFN-γ.  The result indicates that memory CD8+ T cells do exists in the lung.  But, 
some of them may be derived from central memory cells in parabronchial lymph nodes, which are 
recruited to the lung immediately after M. tuberculosis challenge, although we could not detect 
memory CD8+ T cells in the MLN [37].   
Our vaccine was capable of reducing the number of CFU challenged by about 50%, which 
seems to be not enough in terms of clinical relevance. Since we employed a single administration 
of the vaccine expressing a single protective antigen, MPT51, booster vaccines and the vaccine 
expressing several protective antigens could be required for the development of clinically 
effective vaccine. 
As memory T cells present in the lung have been reported to contribute mainly to protection of 
the host from secondary airway infection [38], the results in the present study suggest that 
lentivirus TB vaccine represents a promising novel TB vaccine capable of potent mucosal T-cell 
immune responses.   
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Figure legends 
 
 
 
 
 
 
 
 
 
 
Fig. 1.  EGFP expression of cells in BALF of MPT51 lentivirus-administered mice.  Mice were intratracheally administered with 
MPT51 lentivirus and EGFP expression was measured by a flow cytometry every one week for six weeks after MPT51 lentivirus 
administration.  Representative data are shown from three independent data which showed similar results.  Percentages in the 
figure indicate those of EGFP-positive cells in total cells in BALF.   
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.  MPT51 p24-32-specific CD8+ T cells in the lungs, MLN, and spleens of mice intratracheally-administered with MPT51 
lentivirus.  Mononuclear cells were harvested from the lungs, MLN, and spleens of immunized mice and double-stained with 
anti-CD8 mAb and MPT51 p24-32/H2-Dd tetramer and measured by a flow cytometry.  Representative data of 1 to 6 weeks after 
MPT51 lentivirus administration are shown.  Percentages in the figure indicate those of tetramer-positive cells in CD8+ cells. 
 Hashimoto et al., manuscript for Vaccine 
 18
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.  Detection of MPT51 p24-32-specific memory CD8+ T cells in the lungs of mice intratracheally-administered with MPT51 
lentivirus.  The lung and the MLN mononuclear cells were harvested from immunized mice 10 weeks after MPT51 lentivirus 
administration or from naïve mice and double-stained with anti-CD8 mAb and MPT51 p24-32/H2-Dd tetramer and measured by a 
flow cytometry.  Representative data are shown from three independent data which showed similar results.  Percentages in the 
figure indicate those of the tetramer-positive cells in CD8+ cells. 
 
 
 
 
 
 
 
 
Fig. 4.  Induction of protective immunity against virulent M. tuberculosis infection with MPT51 lentivirus vaccination.  Mice 
were immunized with a single intratracheal administration of MPT51 lentivirus.  The MPT51 lentivirus-immunized mice or naïve 
mice were challenged with intratracheal injection of 1 × 104 CFU of M. tuberculosis H37Rv.  Five weeks after the challenge, the 
numbers of the challenged bacillus in the lungs were counted.  The means ± SD from 6 mice per each group are shown.   
